Home > Insider Trading > Filing (0001662579-25-000019)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1662579	C4 Therapeutics Inc.	CCCC	Biological Products, (No Disgnostic Substances) (2836)	475617627

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1913897	N Scott Boyle	C/O C4 Therapeutics, Inc. 490 Arsenal Way #120 Watertown MA 02472	Chief Business Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2025-02-13	1,735	$3.20	54,832	No	4	F	Direct
Common Stock	Acquisiton	2025-02-14	56,500	$0.00	111,332	No	4	A	Direct
Common Stock	Disposition	2025-02-14	490	$3.15	110,842	No	4	S	Direct
Common Stock	Disposition	2025-02-14	2,368	$3.18	108,474	No	4	F	Direct
Common Stock	Disposition	2025-02-18	669	$3.15	107,805	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	F	Direct
No	4	A	Direct
No	4	S	Direct
No	4	F	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2025-02-14	84,700	$0.00	84,700	$3.18

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
84,700		2035-02-13	No	4	A	Direct

Footnotes

Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") and does not represent a sale by the Reporting Person.
Represents RSUs. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2026.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2024.
The shares underlying this option shall vest and become exercisable in forty-eight equal monthly installments following the grant date, with the first installment vesting on March 14, 2025.